Lupin Launches Clobetasol Propionate Spray in the US
Pharma major Lupin has announced the launch of its Clobetasol Propionate Spray 0.05% having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s spray is the generic equivalent of Galderma Laboratories, L.P.’s Clobex Spray, 0.05%. It is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older.
The spray 0.05% had annual sales of approximately $30.5-mn in the US (IQVIA MAT January 2018).
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-29
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA approves bemotrizinol, a long-used UV filter, for U.S. sunscreens
-
FDA delays proposal to ban formaldehyde in hair straighteners
-
Can Florida's Authorization to Import Prescription Drugs from Canada Lower Medication Prices?
-
FDA Releases New Resources for Food Traceability Final Rule Compliance
-
IFSAC Unveils 2021 Report: Diverse Food Sources Linked to Salmonellosis Cases
-
FDA to Nationwide Ban Brominated Vegetable Oil (BVO) in Food
-
FDA Issues Warning to Produce Importer for Non-Compliance
-
FDA Proposes Ban on Hair Relaxers Containing Formaldehyde
-
US FDA Issues Alert: High Lead Levels Detected in Baby Fruit Puree
-
Yehui Pharmaceuticals' BN104 Receives Fast Track Designation from FDA for the Treatment of Relapsed/Refractory Acute Leukemia
Recommend Reading
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
West Asia Tensions Squeeze Pharma Raw Materials
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
BASF Raises API and Excipient Prices
-
IPEC Updates Excipient Qualification Guidance
-
Premium Global Chemical Sourcing Requests (29 Nov - 3 Dec 2025)
-
September in the Textile Industry: Peak Season Fails to Deliver Strong Performance; Weak Demand and Rising Costs Drive Market Decline
-
ANVISA Updates Additive Rules
-
Costs Decline as September DOP Prices Fluctuate and Fall
-
The Golden September Lacks Luster, Phthalic Anhydride Prices Stabilize at the Bottom in September